Fortress Biotech Inc Pref Series A (FBIOP)vsMerck & Company Inc (MRK)
FBIOP
Fortress Biotech Inc Pref Series A
$15.87
-0.87%
HEALTHCARE · Cap: $77.81M
MRK
Merck & Company Inc
$141.16
-0.63%
HEALTHCARE · Cap: $360.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 97129% more annual revenue ($66.57B vs $68.47M). FBIOP leads profitability with a 163.3% profit margin vs 4.8%. FBIOP earns a higher WallStSmart Score of 44/100 (D).
FBIOP
Hold44
out of 100
Grade: D
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$13.01
Current Price
$15.87
$2.86 discount
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$141.16
$57.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 79 in profit
Keeps 163 of every $100 in revenue as profit
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Trading at 8.3x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : FBIOP
The strongest argument for FBIOP centers on Return on Equity, Profit Margin. Profitability is solid with margins at 163.3% and operating margin at -53.5%. Revenue growth of 14.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : FBIOP
The primary concerns for FBIOP are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
FBIOP profiles as a mature stock while MRK is a value play — different risk/reward profiles.
FBIOP carries more volatility with a beta of 1.25 — expect wider price swings.
FBIOP is growing revenue faster at 14.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
FBIOP scores higher overall (44/100 vs 36/100), backed by strong 163.3% margins and 14.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortress Biotech Inc Pref Series A
HEALTHCARE · BIOTECHNOLOGY · USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?